FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912558647> ?p ?o ?g. }

• W2912558647 abstract "331 Background: Varlitinib is a nanomolar inhibitor of EGFR, HER2, and HER4 and has shown potent anti-tumor activity as monotherapy in preclinical BTC models. During Phase (Ph) 1 development, significant tumor shrinkage was observed in biliary tract cancer (BTC) patients (pts). Tissue microarray analysis has revealed that ~70% of BTC pts exhibit HER overexpression, suggesting varlitinib could be beneficial in BTC. Methods: Data from BTC pts were pooled from 3 Ph1 trials of varlitinib (dosed 200-500 mg BID) in combination with cisplatin and 5-FU/capecitabine (cape) (Study 002); oxaliplatin and 5-FU/cape (Study 002SG); cisplatin and gemcitabine (Study 007). The depth of tumor response, disease control rate (DCR), and treatment-related adverse events (TRAEs) were analysed. Results: As of 12 June 2018, 43 pts were recruited: 12 (27.9%); 10 (23.3%) and 21 (48.8%) from study 002; 002SG and 007 respectively. 002SG and 007 were still ongoing at data cut-off. 20 (46.5%) pts were male and the median age was 62 years (range 42-82). Most tumors were cholangiocarcinoma (74.4%), followed by gallbladder cancer (16.3%) and carcinoma of the Ampulla of Vater (9.3%). 14 (32.6%) pts had received ≥ 1 prior lines of treatment. Of the 37 pts evaluable for efficacy (those with measurable disease and received ≥ 1 dose of treatment), partial responses were observed in 10 (27.0%) pts and stable disease in 16 (43.2%) pts, with a DCR of 70.3%. The median depth of tumor response was -10.8% (range 49.5% to -87.1%). Of 43 pts, the most frequent (≥ 30%) TRAE (any grade) were fatigue (37%), decreased appetite (34%), and nausea (32%) and the most common Grade ≥ 3 TRAE were hyperbilirubinemia (12%), increased AST (9%), and neutropenia (9%). The median PFS data is not matured and will be provided if evaluable at the time of presentation. Conclusions: Varlitinib with platinum-based chemotherapy has a promising efficacy and safety profile in BTC. A Ph2/3 randomised study of varlitinib and cape in 2nd line BTC and a Ph1b/2 study of varlitinib with platinum-based chemotherapy in 1 st line BTC are ongoing. Clinical trial information: NCT02648425, NCT02435927, and NCT02992340." @default.
• W2912558647 created "2019-02-21" @default.
• W2912558647 creator A5004987247 @default.
• W2912558647 creator A5026090288 @default.
• W2912558647 creator A5039240493 @default.
• W2912558647 creator A5043439053 @default.
• W2912558647 creator A5054400789 @default.
• W2912558647 creator A5056408400 @default.
• W2912558647 creator A5059766169 @default.
• W2912558647 creator A5082487227 @default.
• W2912558647 creator A5088403164 @default.
• W2912558647 creator A5088559479 @default.
• W2912558647 date "2019-02-01" @default.
• W2912558647 modified "2023-09-27" @default.
• W2912558647 title "Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies." @default.
• W2912558647 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.331" @default.
• W2912558647 hasPublicationYear "2019" @default.
• W2912558647 type Work @default.
• W2912558647 sameAs 2912558647 @default.
• W2912558647 citedByCount "9" @default.
• W2912558647 countsByYear W29125586472019 @default.
• W2912558647 countsByYear W29125586472020 @default.
• W2912558647 countsByYear W29125586472021 @default.
• W2912558647 countsByYear W29125586472022 @default.
• W2912558647 crossrefType "journal-article" @default.
• W2912558647 hasAuthorship W2912558647A5004987247 @default.
• W2912558647 hasAuthorship W2912558647A5026090288 @default.
• W2912558647 hasAuthorship W2912558647A5039240493 @default.
• W2912558647 hasAuthorship W2912558647A5043439053 @default.
• W2912558647 hasAuthorship W2912558647A5054400789 @default.
• W2912558647 hasAuthorship W2912558647A5056408400 @default.
• W2912558647 hasAuthorship W2912558647A5059766169 @default.
• W2912558647 hasAuthorship W2912558647A5082487227 @default.
• W2912558647 hasAuthorship W2912558647A5088403164 @default.
• W2912558647 hasAuthorship W2912558647A5088559479 @default.
• W2912558647 hasConcept C121608353 @default.
• W2912558647 hasConcept C126322002 @default.
• W2912558647 hasConcept C143998085 @default.
• W2912558647 hasConcept C197934379 @default.
• W2912558647 hasConcept C2776534502 @default.
• W2912558647 hasConcept C2776694085 @default.
• W2912558647 hasConcept C2777909004 @default.
• W2912558647 hasConcept C2778239845 @default.
• W2912558647 hasConcept C2778822529 @default.
• W2912558647 hasConcept C2780258809 @default.
• W2912558647 hasConcept C2780962732 @default.
• W2912558647 hasConcept C31760486 @default.
• W2912558647 hasConcept C526805850 @default.
• W2912558647 hasConcept C535046627 @default.
• W2912558647 hasConcept C71924100 @default.
• W2912558647 hasConcept C90924648 @default.
• W2912558647 hasConceptScore W2912558647C121608353 @default.
• W2912558647 hasConceptScore W2912558647C126322002 @default.
• W2912558647 hasConceptScore W2912558647C143998085 @default.
• W2912558647 hasConceptScore W2912558647C197934379 @default.
• W2912558647 hasConceptScore W2912558647C2776534502 @default.
• W2912558647 hasConceptScore W2912558647C2776694085 @default.
• W2912558647 hasConceptScore W2912558647C2777909004 @default.
• W2912558647 hasConceptScore W2912558647C2778239845 @default.
• W2912558647 hasConceptScore W2912558647C2778822529 @default.
• W2912558647 hasConceptScore W2912558647C2780258809 @default.
• W2912558647 hasConceptScore W2912558647C2780962732 @default.
• W2912558647 hasConceptScore W2912558647C31760486 @default.
• W2912558647 hasConceptScore W2912558647C526805850 @default.
• W2912558647 hasConceptScore W2912558647C535046627 @default.
• W2912558647 hasConceptScore W2912558647C71924100 @default.
• W2912558647 hasConceptScore W2912558647C90924648 @default.
• W2912558647 hasLocation W29125586471 @default.
• W2912558647 hasOpenAccess W2912558647 @default.
• W2912558647 hasPrimaryLocation W29125586471 @default.
• W2912558647 hasRelatedWork W2008702706 @default.
• W2912558647 hasRelatedWork W2009590010 @default.
• W2912558647 hasRelatedWork W2015608796 @default.
• W2912558647 hasRelatedWork W2413499351 @default.
• W2912558647 hasRelatedWork W2413667094 @default.
• W2912558647 hasRelatedWork W2751395222 @default.
• W2912558647 hasRelatedWork W2912558647 @default.
• W2912558647 hasRelatedWork W2981418768 @default.
• W2912558647 hasRelatedWork W3044769365 @default.
• W2912558647 hasRelatedWork W582479186 @default.
• W2912558647 isParatext "false" @default.
• W2912558647 isRetracted "false" @default.
• W2912558647 magId "2912558647" @default.
• W2912558647 workType "article" @default.